ACACA and metabolic dysfunction-associated steatotic liver disease: ACC1/2 dual inhibitors have emerged as leading lipogenesis modulators for the treatment of MASLD due to their robust effects in DNL rates and IHTG levels in patients with MASLD (Table 1).